The current concept for the cardiac glycoside receptor

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Biochemistry

Background:

• Cardiac glycosides are drugs used to treat heart failure.
• The Na+,K+-ATPase (sodium-potassium pump) is crucial for maintaining cell membrane potential and ion gradients.
• Understanding the interaction between cardiac glycosides and the Na+,K+-ATPase is key to their therapeutic effects and toxicity.

Purpose of the Study:

• To highlight the Na+,K+-ATPase as the primary pharmacological receptor for cardiac glycosides.
• To describe the properties and regulation of the Na+,K+-ATPase in relation to glycoside binding.
• To review the correlation between cardiac glycoside inotropic action, pump inhibition, and intracellular ion concentrations.

Main Methods:

• Review of existing literature on cardiac glycosides and Na+,K+-ATPase.
• Analysis of studies correlating drug binding to pump inhibition.
• Discussion of intracellular calcium (Ca2+) and sodium (Na+) concentration effects on pump activity.

Main Results:

• The Na+,K+-ATPase functions as the direct receptor for cardiac glycosides.
• Glycoside binding and Na+,K+-ATPase inhibition are linked to the drug's inotropic effects.
• Intracellular Na+ and Ca2+ levels are correlated with Na+,K+-ATPase inhibition.

Conclusions:

• The Na+,K+-ATPase is the critical target for cardiac glycosides.
• Physiological regulation of cardiac contractility may involve endogenous digitalis-like substances acting on the Na+,K+-pump.
• Further research can refine understanding of cardiac glycoside mechanisms and endogenous regulation.